Harpel P C
J Exp Med. 1970 Aug 1;132(2):329-52. doi: 10.1084/jem.132.2.329.
Activation of plasma kallikrein arginine esterase activity by kaolin resulted in peak activity at 1 min of incubation and a 50% reduction in activity at 5 min in normal plasma, and 30% reduction in the plasma of patients with hereditary angioneurotic edema who lacked the C1 inactivator. The peak esterolytic activity was inhibited by soybean trypsin inhibitor whereas the 5 min activity was resistant to this inhibitor. Acid treatment of normal and hereditary angioneurotic edema plasma destroyed the factor responsible for the fall in esterase activity at 5 min and the factor which rendered the esterase resistant to soybean trypsin inhibitor. Purified alpha(2)-macroglobulin inhibited approximately 50% of the TAMe esterase activity of purified plasma kallikrein without changing its activity toward basic amino acid esters. The interaction between the alpha(2)-macroglobulin and kallikrein resulted in alterations in the gel filtration chromatographic pattern of the TAMe esterase and biologic activity of kallikrein, indicating that kallikrein was bound to the alpha(2)-macroglobulin. The TAMe esterase activity of this complex, isolated by column chromatography, was resistant to C1 inactivator and SBTI. Studies of incubation mixtures of kallikrein, alpha(2)-macroglobulin and C1 inactivator suggested that these inhibitors compete for the enzyme, and that the alpha(2)-macroglobulin partially protects the esterase activity of kallikrein from C1 inactivator. The alpha(2)-macroglobulin isolated from kaolin-activated plasma possessed 240 times the esterolytic activity of the alpha(2)-macroglobulin purified from plasma treated with inhibitors of kallikrein and of its activation. The alpha(2)-macroglobulin blocked the uterine-containing activity and vascular permeability-inducing effects of plasma kallikrein. These studies suggest that the alpha(2)-macroglobulin is a major plasma inhibitor of kallikrein and provide a new example of an interrelationship between the coagulation, fibrinolytic, and kallikrein enzyme systems.
高岭土激活血浆激肽释放酶的精氨酸酯酶活性,在正常血浆中孵育1分钟时活性达到峰值,5分钟时活性降低50%,而在缺乏C1灭活剂的遗传性血管性水肿患者血浆中活性降低30%。峰值酯解活性受到大豆胰蛋白酶抑制剂的抑制,而5分钟时的活性对该抑制剂具有抗性。对正常血浆和遗传性血管性水肿血浆进行酸处理,破坏了导致5分钟时酯酶活性下降的因子以及使酯酶对大豆胰蛋白酶抑制剂产生抗性的因子。纯化的α2-巨球蛋白抑制了纯化的血浆激肽释放酶约50%的TAMe酯酶活性,而不改变其对碱性氨基酸酯的活性。α2-巨球蛋白与激肽释放酶之间的相互作用导致TAMe酯酶的凝胶过滤色谱图谱和激肽释放酶的生物学活性发生改变,表明激肽释放酶与α2-巨球蛋白结合。通过柱色谱分离得到的该复合物的TAMe酯酶活性对C1灭活剂和SBTI具有抗性。对激肽释放酶、α2-巨球蛋白和C1灭活剂孵育混合物的研究表明,这些抑制剂竞争该酶,并且α2-巨球蛋白部分保护激肽释放酶的酯酶活性免受C1灭活剂的影响。从高岭土激活血浆中分离出的α2-巨球蛋白的酯解活性是从用激肽释放酶及其激活抑制剂处理的血浆中纯化得到的α2-巨球蛋白的240倍。α2-巨球蛋白阻断了血浆激肽释放酶的子宫收缩活性和血管通透性诱导作用。这些研究表明,α2-巨球蛋白是激肽释放酶的主要血浆抑制剂,并为凝血、纤溶和激肽释放酶酶系统之间的相互关系提供了一个新的例子。